Drug Profile
Research programme: solid tumour therapeutics - Incuron
Alternative Names: CBL 0175; CBLC100 series; CuraxinsLatest Information Update: 02 Sep 2021
Price :
$50
*
At a glance
- Originator Cleveland BioLabs
- Developer Statera BioPharma
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; DNA intercalators; NF-kappa B inhibitors; SSRP1 protein inhibitors; Tumour suppressor protein p53 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 01 Sep 2021 Cytocom is now called Statera BioPharma
- 28 Jul 2021 Cytocom has been merged with Cleveland BioLabs to form Cytocom
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)